RESEARCH PAPER
Alpha-ketoglutarate partially protects newborns from metabolic changes evoked by chronic maternal exposure to glucocorticoids
 
More details
Hide details
1
Department of Biochemistry and Animal Physiology, Faculty of Veterinary Medicine, Agricultural University, Lublin, Poland
2
Department of Comparative Anatomy and Anthropology, Maria Curie-Skłodowska University, Lublin, Poland
3
Department of Cell and Organism Biology, Lund University,Lund, Sweden
CORRESPONDING AUTHOR
Ewa Śliwa   

Department of Animal Physiology, Faculty of Veterinary Medicine, Agricultural University, Akademicka 12, 20-950 Lublin,
 
J Pre Clin Clin Res. 2007;1(1):55–59
KEYWORDS
ABSTRACT
Foetal and neonatal time is very important for the growth and development of the mechanisms involved in the programming of metabolic processes in adult life. In foetal life, critical developmental time-windows for different key factors determining the programming of metabolic processes persisting for a longer time in later life were discovered. Dexamethasone (Dex), a synthetic glucocorticoid is administered in pregnancy to reduce mortality in preterm infants. However, other studies did not examine the effects of maternal simultaneous dexamethasone treatment with alpha-ketoglutarate (AKG) on glucose, total cholesterol, triacylglycerol and other metabolic markers in the blood serum of newborns. This study shows that exposure to maternal dexamethasone excess during the last 45 days of pregnancy resulted in reduced body weight by 26% in newborns. Moreover, when dexamethasone was administered with AKG, body weight was reduced by only 13.5% when compared with the control group. Total cholesterol concentrations in sows and their newborns in the Dex groups were higher by 81% and 79% compared with the control values in sows and in newborns, respectively. Triacylglycerol serum concentrations were higher by 54% in sows from the Dex group and 58% in newborn piglets born by these mothers. Glucose concentration was higher by 142% in newborns after maternal dexamethasone treatment, compared with the control group. Serum glucose concentration remained unchanged in sows after simultaneous dexamethasone administration with AKG, but in newborns a 2-fold increase was observed. These foetal metabolic changes after maternal treatment with dexamethasone might be linked not only with long lasting metabolic disturbances, but also with more frequent coronary heart and cardiovascular diseases in later life. Our results indicate that maternal AKG administration to sows during the last 45 days of pregnancy protects newborns from metabolic disturbances induced by dexamethasone acting at this time and influencing developmental programming of metabolic processes which may persist or appear in later life.
 
REFERENCES (45)
1.
Dodic M, Moritz K, Koukoulas I, Wintour M: Programmed hypertension: kidney, brain or both? Trends in Endocrin and Metabol 2002, 13, 403- ,408.
 
2.
Ingelfinger JR, Woods LL: Prenatal programming, renal development and adult renal function. Am J Hyperten 2002, 15, 465-495.
 
3.
Smith NH, Ozanne SE: Intrauterine origins of metabolic disease. Rev Gynecol Perinatal Practice 2006, 6, 211-217.
 
4.
D’mello AP, Liu Y: Effects of maternal immobilization stress on birth weight and glucose homeostasis in the offspring. Psychoneuroendocrinol 2006, 31, 395-406.
 
5.
Holemans K, Aerts L, Van Assche A: Fetal growth and long-term consequences in animal models of growth retardation. Eur J Obst6. Holemans K, Aerts L, Van Assche FA: Fetal growth restriction and consequences for the offspring in animal models. J Soc Gynecol Investig 2003, 10, 392-399.
 
6.
consequences for the offspring in animal models. J Soc Gynecol Investig 2003, 10, 392-399.
 
7.
Sun K, Yang K, Challis RG: Glucocorticoid actions and metabolism in pregnancy: implications for placental function and fetal cardiovascular activity. Placenta 1998, 19, 353-360.
 
8.
Bouclaous C, Torbay N, Nassar C, Hwalla N: Modification of glucocorticoid effects on body weight gain, plasma lipids by changes in diet composition. Nutrit Res 2003, 23, 1105-1115.
 
9.
Breier BH, Vickers MH, Ikenasio BA, Chan KY, Wong WPS: Fetalprogramming of appetite and obesity. Mol Cellular Endocrinol 2001,185, 73-79.
 
10.
Fowden AL, Giussani DA, Dino A, Forhead AJ: Endocrine and metabolic programming during intrauterine development. Early Human Development 2005, 81, 723-734.
 
11.
Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR: Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. J Clin Investig 1998, 10, 2174-2181.
 
12.
van Weissenbruch MM, Engelbregt MJ, Veening MA, Delemarre-van de Waal HA: Fetal nutrition and timing of puberty. Endocr Dev 2005, 8, 15-33.
 
13.
Pesty FHR, Sultan F: Glutamine homologues and derivatives: a limiting factor in current artificial nutrition? Nutrition 1997, 13, 575-576.
 
14.
Tapiero H, Mathé G, Couvreur P, Tew KD: II. Glutamine and glutamate. Biomed Pharmac 2002, 56, 446-457.
 
15.
Rogero MM, Tirapegui J, Pedrosa RG, Pires IS, Castro IA: Plasma and tissue glutamine response to acute and chronic supplementation with L-glutamine and L-alanyl-L-glutamine in rats. Nutrit Res 2004, 24,.
 
16.
Chrousos GP: The glucocorticoid receptor gene, longevity, and the complex disorders of western societies. Am J Med 2004, 117, 204-207.
 
17.
Kalhan SC, Gilfillan CA, Tserng K, Savin SM: Glucose-alanine relationship in normal human pregnancy. Metabol 1988, 37, 152-158.
 
18.
Kalhan SC: Protein metabolism in pregnancy. Am J Clin Nutr 2000, 71, 1249S-1255S.
 
19.
Mantha L, Palacios E, Deshaies Y: Modulation of tryglyceride metabolism by glucocorticoids in diet-induced obesity. Am J Physiol 1999, 46, R455-R464.
 
20.
Platt MW, Deshpande S: Metabolic adaptation at birth. Semin Fetal Neonat Med 2005, 10, 341-350.
 
21.
Sassi H, Pictet R, Grange T: Glucocorticoids are insufficient for neonatal gene induction in the liver. Proc Natl Acad Sci USA 1998, 95, 5621- 5625.
 
22.
Śliwa E: Effect of simultaneous versus apart administration of dexamethasone and alpha-ketoglutarate on growth hormone, cortisol and insulin-like growth factor-I in pigs. Bull Vet Inst Pulawy 2006, 50, 205-210.
 
23.
Bayley TM, Alasmi M, Thorkelson T, Jones PJH, Corcoran J, Krug-Wispe S, Tsang R: Longer term effects of early dietary cholesterol level on synthesis and circulating cholesterol concentration in human infants. Metabolism 2002, 51, 25-33.
 
24.
Challis JRG, Sloboda D, Matthews SG, Holloway A, Alfaidy N, Patel FA, Whittle W, Fraser M, Moss TJM, Newnham J: The fetal placental hypothalamic pituitary-adrenal (HPA) axis, parturition and post natal health. Mol Cell Endocrinol 2001, 185, 135-144.
 
25.
Haave NC, Innis SM: Cholesterol synthesis and accretion within various tissues of the fetal and neonatal rat. Metabolism 2001, 50, 12-18.
 
26.
Hahn P, Scrubiski L: Development of cholesterol metabolism, the effect of diet composition at weaning. Biol Neonate 1990, 58, 1-7.
 
27.
Capell WH, Spiegelman KP, Eckel RH: Therapeutic targets in severe hypertriglyceridemia. Drug discovery today: disease mechanisms 2004, 1, 171-177.
 
28.
Diamant S, Shafrir E: Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids. Eur J Biochem 1975, 53, 541- 546.
 
29.
Dourakis SP, Sevastianos VA, Kaliopi P: Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97, 1074- 1075.
 
30.
Kaur N, Sharma N, Gupta AK: Effects of dexamethasone on lipid metabolism in rat organs. Ind J Biochem Bio 1989, 6, 371-376.
 
31.
Nanki T, Koike R, Miyasaka N: Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 1999, 94, 3379-3381.
 
32.
Śliwa E, Tatara MR, Pierzynowski SG: Total cholesterol, glucose and electrolytes in piglets’ serum after alpha-ketoglutarate (AKG) and dexamethasone treatment during prenatal and neonatal life. Bull Vet Inst Pulawy 2006, 50, 561-566.
 
33.
Wang CN, McLeod RS, Yao Z, Brindley DN: Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 1995, 15, 1481- 1491.
 
34.
Bazzano G, Bazzano GS: Hypocholesterolemic effect of α-ketoglutarate in the Mongolian Gerbil. Proc Soc Exp Biol Med 1972, 140, 36-39.
 
35.
Battaglia FC, Thureen PJ: Nutrition of the fetus and premature infant. Nutrition 1997, 13, 903-906.
 
36.
Casado J, Felipe A, Pastor-Anglada M, Remesar X.: Glutamine as a major nitrogen carrier to the liver in suckling rat pups. J Biochem 1988, 256, 377-381.
 
37.
Robinson S, Prendergast CH: Protein metabolism in pregnancy. Clin Endocrinol Metabol 1996, 10, 571-590.
 
38.
Kalhan S, Parimi P: Gluconeogenesis in the fetus and neonate. Semin Perinatal 2000, 24, 94-106.
 
39.
Krampl E, Kametas NA, Zegarra AMC, Roden M, Nicolaides KH: Maternal plasma glucose at high altitude. BJOG 2001, 108, 254-257.
 
40.
Alpers DH: Glutamine: do the data support the cause for glutamine supplementation in human? Gastroenterol 2006, 130, 106-116.
 
41.
Espat NJ, Watkins KT, Lind DS, Weis JK, Copeland EM, Souba WW: Dietary modulation of amino acid transport in rat and human liver. J Surgic Res 1996, 63, 263-268.
 
42.
Parimi PS, Kadrofske MM, Gruca LL, Hanson RW, Kalhan SC: Amino acids, glutamine, and protein metabolism in very low birth weight infants. Pediatr Res 2005, 58, 1259-1264.
 
43.
Green E, Todd B, Health D: Mechanism of glucocorticoid regulation of alkaline phosphatase gene expression in osteoblast-like cells. Eur J Biochem 1990, 188, 147-153.
 
44.
Hadley SP, Hoffmann WE, Kuhlenschmidt MS, Sanecki RK, Dorner JL: Effect of glucocorticoids on alkaline phosphatase, alanine aminotransferase, and gamma-glutamyltransferase in cultured dog hepatocytes. Enzyme 1990, 43, 89-98.
 
45.
Wu G, Haynes TE, Cynthia HL, Meininger CJ: Glutamine metabolism in endothelial cells: ornithine synthesis from glutamine via pyrroline- 5-carboxylate synthase. Comp Biochem and Physiol (Part A) 2000, 126, 115-123.61-270.
 
eISSN:1898-7516
ISSN:1898-2395